Compass Narrows Q3 Loss to $9.8M, Final NDA Filing Due Within Two Weeks
CMPS sits 95% above its 52-week low of $4.88 on elevated volume (5.8× avg).
Summary
Compass reported a Q3 net loss of $9.8 million, or 31c per share, versus $137.7 million a year earlier — the swing is mostly a $40.8 million non-cash warrant fair-value gain, not operations. The operating picture is a company pivoting to launch: R&D fell to $23.5 million from $27.3 million as Phase 3 TRD costs wound down, while SG&A jumped to $33.0 million from $13.2 million on commercial buildout. Cash stands at $444.0 million, up from $149.6 million at year-end, and management says that funds operations into 2028. The real news is regulatory timing: the rolling NDA for COMP360 in TRD is nearly complete, with the final submission due in the next two weeks, and the National Priority Voucher could compress FDA review to 1-2 months ahead of an H1 2027 launch. This follows the September 52-week COMP005 data and the 26-week Phase 3 readout in July that built the filing package.
At the time of this announcement, CMPS was trading at $9.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $4.88 to $15.87. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: BusinessWire.